StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30250% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Janumet (sitagliptin and metformin HCl) by Year

Janumet (sitagliptin and metformin HCl) — International reported growth YoY (%) (%)

Merck Janumet (sitagliptin and metformin HCl): -13.0% in FY2025, up 6.0 pts from a year earlier.

Latest, FY2025
-13.0%
Period ended Dec 31, 2025
Change on a year earlier
+6.0 pts
-19.0% in FY2024
History
7 years
Since FY2017
Sources
7
Documents cited below

Where the FY2025 figure comes from

“|| Janumet | 940 | 935 | 1 | 268 | 161 | 66 | 672 | 774 | -13”

Source: Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗

Reported in Form 8-K Table 3a / 3b Product Sales.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedJanumet (sitagliptin and metformin HCl) — International reported growth YoY (%) (%)Year on yearSource
FY2025Dec 31, 2025-13.0%+6.0 ptsForm 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024-19.0%+10.0 ptsForm 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
FY2023Dec 31, 2023-29.0%–Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
FY2021Dec 31, 20217.0%–Form 8-K (tm222755d1_ex99-1.htm, filed 2022-02-03) ↗
FY2019Dec 31, 20192.0%-7.0 ptsForm 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 20189.0%+3.0 ptsForm 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2017Dec 31, 20176.0%–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Cite this data

StockData. (2026). Merck Janumet (sitagliptin and metformin HCl) (%), annual FY2017–FY2025 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-janumet-intl-nom-yoy

See every metric in the Merck KPI table. Data updated Oct 26, 2026.